Wei Li

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Locally Advanced

Inflammatory Response

Chemotherapy Induced

Top Venues

Expert review of pharmacoeconomics & outcomes research

This page only lists publications with an associated author ORCID identifier.

Publications

Wei Li, Li Wan
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China. Expert review of pharmacoeconomics & outcomes research (2024)
Wei Li, Li Wan
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Wei Li, Li Wan
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China. Expert review of pharmacoeconomics & outcomes research (2024)
Wei Li, Li Wan
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China. Expert review of pharmacoeconomics & outcomes research 24 (5) (2024)
Wei Li, Li Wan
A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China. PloS one 18 (6) (2023)
Wei Li, Li Wan
Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China. BMJ open 13 (9) (2023)
Wei Li, Li Wan, Shaojun Duan, Jingjing Xu
Bibliometric analysis of toll-like receptor agonists associated with cancer therapy. Medicine 101 (1) (2022)